CAR-T player Juno grabs a PhII combo drug in $10M add-on deal
Fresh on the heels of a brief but controversial FDA hold on its lead therapy, Juno has made a small, strategic acquisition, buying Boston-based Redox Therapies.
Redox is only costing Juno $10 million upfront, a rounding error for a fast-moving biotech that is engaged in a race to develop the first CAR-T drug. That plus an unspecified set of milestones is delivering vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that “has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.